Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

Share Price is delayed by 15 minutes
Get Live Data
331.60    -2.40 (-0.72%)
Bid:
331.60
Ask:
331.70
Spread: 0.10 (0.03%)
Market Cap: £29.28b
HLN Live PriceLast checked at - London Stock Exchange

Intraday Haleon Share Chart

Board Changes

5 Dec 2024 10:00

RNS Number : 9658O
Haleon PLC
05 December 2024
 

 

 

Haleon plc: Board Changes

 

5 December 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the following changes to the Board.

 

Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 20%, and in line with the Pfizer Relationship Agreement with Haleon plc, David Denton, Non-Executive Director and

representative of Pfizer Inc., stepped down from the Board on 4 December 2024.

 

Bláthnaid Bergin has been appointed as an independent Non-Executive Director and will join the Haleon Board on 24 February 2025.

 

Bláthnaid Bergin brings financial leadership and strategic planning experience from a variety of consumer-facing businesses. Bláthnaid is currently the Chief Financial Officer of J Sainsbury plc, where she has played a pivotal role in driving the company's financial strategy and operational efficiency initiatives. Prior to joining Sainsbury's, Bláthnaid held senior finance leadership and international positions at Aviva, RSA and GE working across Europe, Asia and Australia. She is a Chartered Accountant. Bláthnaid was previously Non-Executive Director, Chair of the Audit Committee and Senior Independent Director for Artemis Alpha Investment Trust.

 

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Dave for his insights and contributions to the Board's discussions. We wish him all the very best for the future. I would like to welcome Bláthnaid to Haleon. With her strong track record of financial leadership and transformation from multiple consumer-facing businesses, Bláthnaid brings a wealth of relevant skills and experience to the Board."

 

The Company confirms that there is no further information to be disclosed under the requirements of UKLR 6.4.6R and 6.4.8R.

 

Amanda Mellor 

Company Secretary 

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFSLSUIELSEDE
Date   Source Headline
30th Sep 202410:15 amRNSDivestment of NRT business outside US complete
27th Sep 202411:00 amRNSDirector/PDMR Shareholding
27th Sep 202410:00 amRNSHaleon to increase stake in China JV to 88%
26th Sep 20245:48 pmRNSTransaction in Own Shares
25th Sep 20245:13 pmRNSTransaction in Own Shares
23rd Sep 20245:19 pmRNSTransaction in Own Shares
23rd Sep 20242:00 pmRNSDirector/PDMR Shareholding
20th Sep 20246:09 pmRNSTransaction in Own Shares
19th Sep 20246:00 pmRNSTransaction in Own Shares
18th Sep 20245:49 pmRNSTransaction in Own Shares
17th Sep 20245:00 pmRNSTransaction in Own Shares
16th Sep 20245:17 pmRNSTransaction in Own Shares
13th Sep 20245:52 pmRNSTransaction in Own Shares
12th Sep 20245:12 pmRNSTransaction in Own Shares
12th Sep 20247:00 amRNSHaleon plc: EMTN bond offering
11th Sep 20245:04 pmRNSTransaction in Own Shares
11th Sep 20244:52 pmRNSDirector/PDMR Shareholding - amended
10th Sep 20245:14 pmRNSTransaction in Own Shares
10th Sep 20244:50 pmRNSDirector/PDMR Shareholding
9th Sep 20245:08 pmRNSTransaction in Own Shares
9th Sep 20249:15 amRNSEMTN Programme: publication of supplement
6th Sep 20245:26 pmRNSTransaction in Own Shares
5th Sep 20244:53 pmRNSTransaction in Own Shares
4th Sep 20245:13 pmRNSTransaction in Own Shares
3rd Sep 20245:00 pmRNSTransaction in Own Shares
2nd Sep 20245:38 pmRNSTransaction in Own Shares
2nd Sep 20242:45 pmRNSTotal Voting Rights and Capital
30th Aug 20245:04 pmRNSTransaction in Own Shares
29th Aug 20245:28 pmRNSTransaction in Own Shares
28th Aug 20245:03 pmRNSTransaction in Own Shares
27th Aug 20245:09 pmRNSTransaction in Own Shares
23rd Aug 20245:14 pmRNSTransaction in Own Shares
22nd Aug 20245:10 pmRNSTransaction in Own Shares
21st Aug 20245:18 pmRNSTransaction in Own Shares
20th Aug 20245:36 pmRNSTransaction in Own Shares
19th Aug 20244:59 pmRNSTransaction in Own Shares
9th Aug 20246:07 pmRNSTransaction in Own Shares
8th Aug 20245:15 pmRNSTransaction in Own Shares
7th Aug 20245:13 pmRNSTransaction in Own Shares
6th Aug 20245:28 pmRNSTransaction in Own Shares
6th Aug 202410:00 amRNSDirectorate Change
5th Aug 20245:42 pmRNSTransaction in Own Shares
2nd Aug 20246:21 pmRNSTransaction in Own Shares
1st Aug 20247:05 amRNSCommencement of On-Market Share Buyback Programme
1st Aug 20247:00 amRNSHaleon 2024 Half Year Results
26th Jun 202412:45 pmRNSDivestment of NRT business outside of the US
31st May 20244:47 pmRNSDisposal of the ChapStick brand completed
23rd May 20245:15 pmRNSDirector/PDMR Shareholding
20th May 20242:45 pmRNSHolding(s) in Company
20th May 20242:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.